Patents Assigned to OncoTracker, Inc.
  • Diagnostic, prognostic, and monitoring methods for chronic lymphocytic leukemia
    Patent number: 12174189
    Abstract: The invention generally provides improved compositions and methods for detecting, diagnosing, prognosing, and monitoring multiple myeloma, chronic lymphocytic leukemia, or B-cell non-Hodgkin lymphoma in a subject. In particular, the invention provides methods for detecting BCMA in subjects to reliably diagnose, predict survival, or monitor multiple myeloma, chronic lymphocytic leukemia, or B-cell non-Hodgkin lymphoma in the subject.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: December 24, 2024
    Assignee: ONCOTRACKER, INC.
    Inventors: James R. Berenson, Haiming Chen, Eric Sanchez
  • Methods for monitoring immune status of a subject
    Patent number: 11698369
    Abstract: The invention generally provides improved compositions and methods for monitoring immune status of a subject. In particular, the invention provides methods for detecting BCMA in subjects to reliably monitor immune status of the subject.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: July 11, 2023
    Assignee: ONCOTRACKER, INC.
    Inventor: James Richard Berenson
  • Diagnostic, prognostic, and monitoring methods for solid tumor cancers
    Patent number: 11635435
    Abstract: The compositions and methods of the invention relate generally to detection of biomarkers for the diagnosis, prognosis, and monitoring of solid tumor cancers. In particular, the invention relates to compositions and methods for detection of B-cell maturation antigen (BCMA) for the diagnosis, prognosis, and monitoring of solid tumor type of cancers.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: April 25, 2023
    Assignee: ONCOTRACKER, INC.
    Inventor: James Richard Berenson
  • Anti-cancer effects of JAK2 inhibitors in combination with thalidomide derivatives and glucocorticoids
    Patent number: 11246876
    Abstract: The present invention provides methods of treatment for hematological malignancies involving synergistic combination of a JAK2 inhibitor and a glucocorticoid or a JAK2 inhibitor, thalidomide or thalidomide derivative, and a glucocorticoid. The compositions and methods provide an unexpected efficacy in the treatment for hematological disorders. The hematological disorders treated by the current invention include multiple myeloma, and may also include hematological disorders that are refractory to prior cancer treatments, or a relapsed hematologic disorder.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: February 15, 2022
    Assignee: OncoTracker, Inc.
    Inventor: James R. Berenson
  • ANTI-CANCER EFFECTS OF JAK2 INHIBITORS IN COMBINATION WITH THALIDOMIDE DERIVATIVES AND GLUCOCORTICOIDS
    Publication number: 20200030343
    Abstract: The present invention provides methods of treatment for hematological malignancies involving synergistic combination of a JAK2 inhibitor and a glucocorticoid or a JAK2 inhibitor, thalidomide or thalidomide derivative, and a glucocorticoid. The compositions and methods provide an unexpected efficacy in the treatment for hematological disorders. The hematological disorders treated by the current invention include multiple myeloma, and may also include hematological disorders that are refractory to prior cancer treatments, or a relapsed hematologic disorder.
    Type: Application
    Filed: May 7, 2019
    Publication date: January 30, 2020
    Applicant: OncoTracker, Inc.
    Inventor: James R. BERENSON
  • Anti-cancer effects of JAK2 inhibitors in combination with thalidomide derivatives and glucocorticoids
    Patent number: 10363260
    Abstract: The present invention provides methods of treatment for hematological malignancies involving synergistic combination of a JAK2 inhibitor and a glucocorticoid or a JAK2 inhibitor, thalidomide or thalidomide derivative, and a glucocorticoid. The compositions and methods provide an unexpected efficacy in the treatment for hematological disorders. The hematological disorders treated by the current invention include multiple myeloma, and may also include hematological disorders that are refractory to prior cancer treatments, or a relapsed hematologic disorder.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: July 30, 2019
    Assignee: OncoTracker, Inc.
    Inventor: James R. Berenson